Cargando…

Real World Data Comparison of Standard Care vs SDM Laser Vision Protection Therapy for Prevention of Neovascular AMD

PURPOSE: To access the impact of regular periodic subthreshold diode micropulse laser (SDM) as Vision Protection Therapy on the rate of neovascular conversion of dry age-related macular degeneration (AMD). METHODS: Patient unidentified clinical data aggregated by Vestrum Health, LLC (VH) from 300 re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luttrull, Jeffrey K, Gray, Gerry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148208/ https://www.ncbi.nlm.nih.gov/pubmed/35637897 http://dx.doi.org/10.2147/OPTH.S366150

Ejemplares similares

Low incidence of choroidal neovascularization following subthreshold diode micropulse laser (SDM) in high-risk AMD
por: Luttrull, Jeffrey K., et al.
Publicado: (2018)

Vision protection therapy for prevention of neovascular age-related macular degeneration
por: Luttrull, Jeffrey K., et al.
Publicado: (2023)

Subthreshold Diode Micropulse Laser (SDM) for Persistent Macular Thickening and Limited Visual Acuity After Epiretinal Membrane Peeling
por: Luttrull, Jeffrey K
Publicado: (2020)

Subthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review
por: Luttrull, Jeffrey K, et al.
Publicado: (2012)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
por: Mehta, Hemal, et al.
Publicado: (2020)

The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes
por: Butt, Thomas, et al.
Publicado: (2015)

Mechanisms of FH Protection Against Neovascular AMD
por: Borras, Céline, et al.
Publicado: (2020)

Dihydroartemisinin Inhibits Laser-Induced Choroidal Neovascularization in a Mouse Model of Neovascular AMD
por: Li, Xun, et al.
Publicado: (2022)

Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study
por: Bulirsch, Louisa Maria, et al.
Publicado: (2022)

Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting
por: Rübsam, Anne, et al.
Publicado: (2022)

The Impact of Diabetic Retinopathy on the Choriocapillaris in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2023)

Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
por: Lotery, A, et al.
Publicado: (2017)

Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting
por: Lüke, Jan Niklas, et al.
Publicado: (2022)

Discontinuation of treatment and retreatment of neovascular age-related macular degeneration in the real-world: Bundang AMD cohort study report 5
por: Cho, Soo Chang, et al.
Publicado: (2023)

Aqueous Fluid Transcriptome Profiling Differentiates Between Non-Neovascular and Neovascular AMD
por: Kaidonis, Georgia, et al.
Publicado: (2023)

Regulation of signaling events involved in the pathophysiology of neovascular AMD
por: Wang, Haibo, et al.
Publicado: (2016)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

Gains in the current understanding of managing neovascular AMD with brolucizumab
por: Bodaghi, Bahram, et al.
Publicado: (2023)

ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD)
por: Liakopoulos, Sandra, et al.
Publicado: (2020)

Vision Rehabilitation is Part of AMD Care
por: Colenbrander, August
Publicado: (2018)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Ready for SDM: evaluating a train-the-trainer program to facilitate implementation of SDM training in Norway
por: Kienlin, Simone, et al.
Publicado: (2021)

Genetic screening for neovascular AMD: cost effective…not so quick
por: Reichel, Elias
Publicado: (2015)

Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results
por: Neves Cardoso, Pedro, et al.
Publicado: (2017)

New Therapies of Neovascular AMD beyond Anti-VEGF Injections
por: Gahn, Greggory M., et al.
Publicado: (2018)

PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections
por: Banaee, Touka, et al.
Publicado: (2021)

Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD
por: Iqball, Sharifah, et al.
Publicado: (2023)

Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes
por: Arrigo, Alessandro, et al.
Publicado: (2021)

Ranibizumab for the treatment of wet AMD: a summary of real-world studies
por: Chong, V
Publicado: (2016)

SDM2022 workshop group photo
por: Fichet, Jacques Herve
Publicado: (2022)

2191: The SDM learning loop model
por: Ronis, Sarah, et al.
Publicado: (2018)

The Need for Brevity During Shared Decision Making (SDM) for Cancer Screening: Veterans’ Perspectives on an “Everyday SDM” Compromise
por: Caverly, Tanner J., et al.
Publicado: (2021)

Modern retinal laser therapy
por: Kozak, Igor, et al.
Publicado: (2015)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
por: Khoramnia, Ramin, et al.
Publicado: (2021)

Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion
por: Balaskas, Konstantinos, et al.
Publicado: (2021)

The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice
por: Pearce, Ian, et al.
Publicado: (2022)

Cataract surgery in neovascular AMD: impact on visual acuity and disease activity
por: Tang, Hin Yan, et al.
Publicado: (2023)

Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
por: Horner, Faye, et al.
Publicado: (2019)

Simultaneous perception of prosthetic and natural vision in AMD patients
por: Palanker, D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_etlg8a4g9ukbopahdlouqa24el